- Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All
Clinical trials
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke -
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (20210052) - Investigator
- Vandana K Seeram
- Ages
- 40 Years - 99 Years
- Sexes
- All
-
Study of BD ORC Original Absorbable Hemostat Compared with Surgicel簧 Original Absorbable Hemostat - Investigator
- Kethandapatti Balaji
- Ages
- 22 Years - 101 Years
- Sexes
- All
-
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare - Investigator
- Gurjit S Kaeley
- Ages
- 18 Years - 100 Years
- Sexes
- All
-
Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia - Investigator
- Mohammad Ilyas
- Ages
- 0 Years - 12 Years
- Sexes
- All
-
Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Patients Hospitalized for Viral Lung Infection Requiring Supplemental Oxygen - Investigator
- Tracy T Ashby
- Ages
- 18 Years - NA Years
- Sexes
- All
-
Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI) - Investigator
- Francesco Franchi
- Ages
- 18 Years - N/A
- Sexes
- All
-
STOMP study - Investigator
- Mobeen H Rathore
- Ages
- 7 Years - 60 Years
- Sexes
- All
-
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia (20180529) - Investigators
- Mark Hudak, William R Driscoll, Ma Ingyinn, Padma S Nandula, Sanket Shah, Renu Sharma, Winston T Sheen, Josef Cortez, Shalinkumar P Patel, Orlyn C Lavilla, John W Logan, Dawn D McDaniel
- Ages
- N/A
- Sexes
- All
-
A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control - Investigator
- Sandeep Grover
- Ages
- 12 Years - 50 Years
- Sexes
- Male